

James E Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4844925/publications.pdf>

Version: 2024-02-01

47
papers

2,273
citations

257450

24
h-index

254184

43
g-index

47
all docs

47
docs citations

47
times ranked

3516
citing authors

#	ARTICLE	IF	CITATIONS
1	How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. <i>Journal of Urology</i> , 2022, 207, 1048-1056.	0.4	7
2	Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes. <i>BMC Urology</i> , 2022, 22, 28.	1.4	7
3	High prostate-specific membrane antigen (⁶⁸Ga-prostate-specific membrane antigen (⁶⁸Ga-PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. <i>BJU International</i> , 2022, 130, 5-7.	2.5	10
4	Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation—A Multicenter Validation Study. <i>European Urology Focus</i> , 2022, 8, 1591-1598.	3.1	6
5	Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). <i>World Journal of Urology</i> , 2021, 39, 1107-1114.	2.2	18
6	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , 2021, 80, 682-689.	1.9	181
7	Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. <i>European Urology Oncology</i> , 2020, 3, 283-290.	5.4	52
8	Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102860.	4.4	73
9	Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. <i>BJU International</i> , 2020, 125, 369-378.	2.5	25
10	Magnetic Resonance Imaging Improves Selection for Active Surveillance and Can Extend the Interval Between Biopsies. <i>European Urology</i> , 2020, 78, 518-519.	1.9	2
11	Combination of Peri-Tumoral and Intra-Tumoral Radiomic Features on Bi-Parametric MRI Accurately Stratifies Prostate Cancer Risk: A Multi-Site Study. <i>Cancers</i> , 2020, 12, 2200.	3.7	49
12	Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation. <i>BMC Urology</i> , 2020, 20, 81.	1.4	10
13	Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. <i>BJU International</i> , 2020, 125, 515-524.	2.5	51
14	The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies. <i>Journal of Urology</i> , 2020, 203, 910-917.	0.4	44
15	<p>>Quality Assessment and Comparison of Plasma-Derived Extracellular Vesicles Separated by Three Commercial Kits for Prostate Cancer Diagnosis</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 10241-10256.	6.7	16
16	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis. <i>Theranostics</i> , 2020, 10, 2309-2326.	10.0	124
17	Diagnostic accuracy of ⁶⁸Ga-prostate-specific membrane antigen (⁶⁸Ga-PSMA) positron emission tomography (⁶⁸Ga-PSMA PET) and multiparametric (mp) MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of ⁶⁸Ga-PSMA PET to mp MRI. <i>BJU International</i> , 2019, 124, 42-49.	2.5	80
18	Editorial Comment. <i>Journal of Urology</i> , 2019, 201, 306-307.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 818-828.	3.4	88
20	Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. <i>World Journal of Urology</i> , 2018, 36, 1383-1389.	2.2	28
21	Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve—Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases. <i>European Urology</i> , 2018, 73, 664-671.	1.9	59
22	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing. <i>European Urology Focus</i> , 2018, 4, 707-710.	3.1	42
23	MRI improves cost and accuracy of prostate cancer biopsy. <i>Nature Reviews Urology</i> , 2018, 15, 6-8.	3.8	3
24	Focal irreversible electroporation as primary treatment for localized prostate cancer. <i>BJU International</i> , 2018, 121, 716-724.	2.5	74
25	MRI improves active surveillance of prostate cancer however biopsy is still crucial. <i>BJU International</i> , 2018, 122, E1-E2.	2.5	2
26	Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. <i>Lancet, The</i> , 2017, 389, 767-768.	13.7	4
27	Computational imaging reveals shape differences between normal and malignant prostates on MRI. <i>Scientific Reports</i> , 2017, 7, 41261.	3.3	10
28	A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. <i>BJU International</i> , 2017, 120, 774-781.	2.5	98
29	MP53-10 ROBOT-ASSISTED SALVAGE NODE DISSECTION FOR OLIGOMETASTATIC NODAL DISEASE DETECTED BY ⁶⁸ GALLIUM-PSMA PET/CT: A MULTICENTRE RETROSPECTIVE SERIES. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
30	The Role of Robotics in the Invasive Management of Bladder Cancer. <i>Current Urology Reports</i> , 2017, 18, 57.	2.2	4
31	Initial multicentre experience of ⁶⁸ gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. <i>BJU International</i> , 2017, 120, 673-681.	2.5	67
32	Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 184-193.	3.4	114
33	Learning Curves for Robotic Surgery: a Review of the Recent Literature. <i>Current Urology Reports</i> , 2017, 18, 89.	2.2	45
34	Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. <i>BJU International</i> , 2017, 120, 51-58.	2.5	28
35	Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy. <i>Prostate Cancer</i> , 2016, 2016, 1-8.	0.6	13
36	Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies. <i>Prostate Cancer</i> , 2016, 2016, 1-7.	0.6	2

#	ARTICLE	IF	CITATIONS
37	MP80-16 PREDICTING LOW-RISK PROSTATE CANCER FROM TRANSPERINEAL SATURATION BIOPSIES. Journal of Urology, 2016, 195, .	0.4	0
38	Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemiablatable focal therapy. BJU International, 2016, 117, 48-54.	2.5	27
39	The Stockholm-3 (STHLM3) model to improve prostate cancer testing in men 50-69 years compared to current clinical practice.. Journal of Clinical Oncology, 2016, 34, 5050-5050.	1.6	1
40	The risk-based STHLM3 model to improve prostate cancer testing in men 50-69 years: Further health, economic, and clinic evaluation.. Journal of Clinical Oncology, 2016, 34, 36-36.	1.6	0
41	Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. BJU International, 2015, 115, 884-891.	2.5	40
42	Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncology, The, 2015, 16, 1667-1676.	10.7	308
43	Multiparametric Magnetic Resonance Imaging Guided Diagnostic Biopsy Detects Significant Prostate Cancer and could Reduce Unnecessary Biopsies and Over Detection: A Prospective Study. Journal of Urology, 2014, 192, 67-74.	0.4	189
44	Reply to Patrick H. Tuliao and Koon Ho Rha's Letter to the Editor re: James E. Thompson, Sam Egger, Maret BÅrhm, et al. Superior Quality of Life and Improved Surgical Margins Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve: A Prospective Single-surgeon Study of 1552 Consecutive Cases. Eur Urol 2014;65:521-31. European Urology, 2014, 65, e95-e96.	1.9	1
45	Superior Quality of Life and Improved Surgical Margins Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve: A Prospective Single-surgeon Study of 1552 Consecutive Cases. European Urology, 2014, 65, 521-531.	1.9	139
46	The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU International, 2013, 112, 6-20.	2.5	130
47	2220 MAGNETIC RESONANCE IMAGING DETECTS SIGNIFICANT PROSTATE CANCER AND COULD BE USED TO REDUCE UNNECESSARY BIOPSIES: INITIAL RESULTS FROM A PROSPECTIVE TRIAL. Journal of Urology, 2013, 189, .	0.4	2